Yuhan And ProGen Partner To Accelerate The Future Of Innovative Medicines

Yuhan Corp. has announced a broad R&D collaboration agreement with ProGen, a company specializing in next-generation obesity and diabetes treatments using its bispecific antibody platform, NTIG technology. This partnership aims to develop innovative new drug candidates. This collaboration will enhance Yuhan's partnership with ProGen, with both companies jointly working on developing next-generation biologics. They aim to boost their global market competitiveness through a new drug development committee composed of drug development experts from both companies.

ProGen's NTIG technology platform is noted for increasing protein stability and blood half-life, developing multitarget fusion proteins, and creating dual-target ADCs, making it highly scalable for various diseases. As part of the agreement, an immuno-oncology bispecific antibody has been chosen as the initial joint development project, with discussions ongoing to identify future joint development projects.

Cho Wook-je, CEO of Yuhan Corp. said, “Through this comprehensive R&D collaboration agreement, we will continue to exchange technologies and collaborate with ProGen. We look forward to securing a pipeline of globally competitive and innovative drugs."